Ultrasonography is not inferior to fluoroscopy to guide extracorporeal shock waves during treatment of renal and upper ureteric calculi : a randomized prospective study by Van Besien, Jeroen et al.
Research Article
Ultrasonography Is Not Inferior to Fluoroscopy to Guide
Extracorporeal Shock Waves during Treatment of Renal and
Upper Ureteric Calculi: A Randomized Prospective Study
Jeroen Van Besien,1 Pieter Uvin,1 Isabeau Hermie,2 Thomas Tailly,3 and Luc Merckx1
1Department of Urology, AZ Sint-Lucas, Ghent, Belgium
2Department of Radiology, AZ Sint-Jan, Bruges, Belgium
3Department of Urology, University Hospitals, Ghent, Belgium
Correspondence should be addressed to Jeroen Van Besien; jeroen.vanbesien@gmail.com
Received 26 January 2017; Accepted 29 March 2017; Published 15 May 2017
Academic Editor: Adair Santos
Copyright © 2017 Jeroen Van Besien et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objective. To investigate whether the visualization modality (ultrasound or fluoroscopy) used during shockwave lithotripsy (SWL)
affects the clinical outcome in those instances where both imaging modalities are optional.Methods. Between November 2014 and
July 2016, 114 patients with radiopaque upper urinary tract calculi were randomly assigned to an ultrasound- or fluoroscopy-guided
SWL group in a prospective, open-label, single-center study. A standardized SWL protocol was used. The stone-free rate and the
positive outcome rate (stone-free or asymptomatic residual fragments≤ 4mm)were compared.Results.The stone-free rate was 52%
in the ultrasound-guided group compared to 42% in the fluoroscopy-guided group (𝑝=0.06) and the positive outcome ratewas 79%
in the ultrasound-guided group compared to 70% in the fluoroscopy-guided group (𝑝 = 0.28). These results were not significantly
different but proved to be noninferior based on a Wilson confidence interval of independent proportions (noninferiority limit
10%). The mean number of SWL sessions was not significantly different (𝑝 = 0.4). Conclusion. Our study demonstrated that the
clinical results of ultrasound-guided SWL were not inferior to the results of fluoroscopy-guided SWL, while no ionizing radiation
is needed.
1. Introduction
Extracorporeal shock wave lithotripsy (SWL) is a well known
technique that has been used since the early eighties for the
treatment of urinary stones [1]. Currently, there is a trend
towards the preferred use of minimally invasive endoscopic
procedures such as (flexible) ureteroscopy or (mini-) per-
cutaneous nephrolithotomy for the treatment of renal or
pyelum stones. Despite this evolution, SWL remains one of
the preferred treatment options for renal stones < 20mm [2].
SWLhas a low complication rate and does not require general
anesthesia [3].
The success rates for SWL vary strongly, as stone-free
rates for renal and ureteric stones of 32–90% and 43–98%,
respectively, have been reported [4].The success rate depends
on several patient and stone related factors, as well as
treatment protocol and operator experience [4–9].
It is crucial for the success of SWL to correctly visualize
the stone in order to focus the shock waves as precisely as
possible, which is done by ultrasonography (US) (B–scan
ultrasound) or fluoroscopy (FS) (X-rays). Radiopaque stones
located in the kidney calices, the renal pelvis, or the uretero-
pelvic junction (UPJ) can often be visualized by both US and
FS. In this paper these stones will be named upper urinary
tract stones (UUTS). To the best of our knowledge, a head-
on comparison of FS-guided versus US-guided SWL has not
been reported in the published literature.
This study aimed to investigate whether the visualization
modality affects the clinical outcome of SWL in those stones
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Figure 1: Outline of enrollment.
2. Materials and Methods
This study was approved by the institutional review board
of Sint-Lucas Hospital Ghent and all patients signed an
informed consent form. Outline of enrollment is depicted
in Figure 1. Indications and exclusion criteria for SWL were
according to the 2015 EAU guidelines on urolithiasis [2]. The
study was performed between November 2014 and July 2016.
Patients with radiopaque UUTS were eligible to be enrolled
in this prospective single-center study. Prior to the treatment,
all patients were randomized to an US-guided or a FS-guided
SWLgroupbased on a randomized list generated by statistical
software. If a stone was not visible on abdominal radiograph
and ultrasound, the patient was excluded from the study.
The radiologist was blinded for the randomization process.
Practitioner and patient were not. These SWL sessions have
been carried out by only two practitioners. Both practitioners
were used to performing renal ultrasonography in daily
practice and had performed multiple US-guided and FS-
guided SWL procedures prior to the start of the study. Their
experience level with both techniques was equal.
Prior to the treatment, the size of the stone was measured
by the radiologist by plain abdominal radiography using the
maximal stone diameter [10]. The locations of the stones
in the urinary tract were described as upper pole stones,
midpolar stones, lower pole stones, or renal pelvis/UPJ
stones. Sixty out of 114 patients that completed the study
received a low dose noncontrast CT scan of the abdomen
(5mSv). In these patients, stone density (measured by mean
and maximal Hounsfield units) and skin-to-stone distance
(45∘ and 90∘) were noted. SWLwas performed on ambulatory
basis using a diclofenac 100mg sustained release suppository
for analgesia [11]. SWL was performed with a 3rd genera-
tion Dornier Compact Sigma (Dornier MedTech, Munich,
Germany). Fluoroscopic visualization was performed with
a mobile digital C-Arm (Series 7700 OEC Medical Sys-
tems, General Electric, Boston, United States). Ultrasono-
graphic visualization was done with a mobile ultrasonogra-
phy machine (Flexfocus 400 BK Medical, Analogic, Boston,
United States). The ultrasonographic visualization allowed
real timemonitoring of the SWL procedure by using hit/miss
monitoring through spectral Doppler ultrasound [12].
The SWL protocol was standardized. The stone was
positioned in the expiratory phase [13]. SWL was applied
with patients in the supine position with a frequency of 1Hz.
A specific and standardized ramping protocol was applied.
Energy was started at the lowest energy level possible with the
SWL device. After 60-120-180-360 and 600 shocks the energy
level was raised by one level. If the patient could not endure
the discomfort created by the shock wave, the energy was
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Figure 2: Seven possible outcomes after SWL sessions. (1) Drop out: patients refusing to further participate in the study or not attending
follow-up visit after maximally 3 weeks (2) Positive endpoint: Stone-free patients. Follow-up visit after 1 year. (3) Positive endpoint: Asymp-
tomatic residual fragments ≤ 4mm. Follow-up visit after 6 months. (4) Negative endpoint: Additional therapy needed. Ureterorenoscopy,
percutaneous nephrolithotomy, placement of an ureteric stent, or SWL on an ureteric stone no longer visible by ultrasound because of the
location in the ureter. (5) Negative endpoint: No effect. No iconographic reduction in stone size and no gravel in the urine after 2 SWL sessions.
(6) Intermediate outcome: Asymptomatic residual fragments ≥ 5mm. Patients were proposed a second, third, or maximally fourth SWL
session. (7) Intermediate outcome: Symptomatic residual fragments. Patientswere proposed a second, third, ormaximally fourth SWL session.
lowered by one level for 120 shocks before attempting to raise
the energy level again. At the end of the procedure, amaximal
total shock wave energy of 62 Joule could be obtained in a
patient that endured the ramping protocol completely. The
duration of the positioning of the patient wasmeasured using
a timer. This timer started from the moment the patient was
positioned on the treatment table until the first shock was
given.
For the fluoroscopy group the window was collimated
to a 7 × 7 cm window after focusing of the stone. Intermit-
tent fluoroscopy was used. Positioning was adjusted at the
beginning of the SWL session and after every 300 shocks or
when patients moved. The number of position changes was
noted. If disintegration of the stone was visible, the energy
level was not raised in this group. Dose area product (DAP)
and fluoroscopy time was noted after each session.
For the ultrasonography group, positioning was adjusted
at the beginning of the SWL session and further based on
real time monitoring of the stone localization. The number
of position changes was noted.
After the SWL session, patients were discharged and were
instructed to void in a stone sieve and to take once daily
tamsulosin 0.4mg until the next visit [14]. Two or three weeks
after every SWL session, follow-up imaging (ultrasound and
plain abdominal radiography) was performed by a radiolo-
gist. Residual stone size was estimated on plain abdominal
radiography.
After each SWL session there were 7 possible outcomes,
which are depicted in Figure 2. The primary outcome of this
study was the number of patients with a stone-free status
or the presence of only asymptomatic residual fragments of
4mm or less after a maximum of four SWL sessions.This was
defined as a positive outcome [15]. The absence of any result
after two SWL sessions or the need for supplementary therapy
was defined as a negative outcome. Declining further partici-
pation in the study or not attending follow-up consultation
after SWL was defined as drop out. Secondary outcomes
were the number of SWL sessions needed, positioning time,
number of repositions, and dose area product.
All stone fragments were sent for examination by Fourier
transform infrared spectroscopy. All patients were offered a
further metabolic evaluation with a 24-hour urine collection.
Prior to the start of the study, a statistical power anal-
ysis for noninferiority studies was performed. Sample size
estimation was based on our own retrospective data. To
maintain 80% power with a significance level of 5% and a
noninferiority level of 10% the projected sample size needed
with this effect size was 57 patients per group. Adjusting for
10% loss to follow-up we recruited 126 patients. Noninferi-
ority for the primary outcome was tested based on a 95%
Wilson confidence interval for 2 independent proportions
with the noninferiority limit set at 10%. Mann–Whitney 𝑈
and unpaired 𝑇-test were performed for secondary outcomes
where appropriate, considering a 𝑝 value of <0.05 to indicate
statistical significant difference. Statistical analysis was per-
formed with IBM SPSS Statistics version 23.
3. Results
3.1. Factors Influencing SWL Outcome. One hundred and
fourteen patients participated in this study. Both the US
group and the FS group contained 57 patients. Most factors
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that could potentially influence the SWL outcome were not
significantly different in both groups (Table 1). The mean
stone size was 9mm in the US group versus 8.5mm in the
FS group (p = 0.29). Only 55 patients (48%) were able to
catch a fragment in a stone sieve. Thirty stone analyses were
performed in the US group and 25 in the FS group. The
US group harboured 6 “very hard” stones (Calcium Oxalate
Monohydrate, brushite, or cystine stones [16]) compared to
4 in the FS group (p = 0.50). The position of the stones in
the urinary tract differed (althoughnot significantly) between
both groups but the number of lower pole stones (which are
known for their limited positive outcome after SWL [17]) was
22 in both groups. Mean and maximal stone densities were
not significantly different in both groups (p = 0.10).Themean
and maximal stone densities were 665HU and 965HU in
the US group versus 740HU and 1213HU in the FS group.
Due to the standardized study protocol, shock frequency,
number of shocks, and ramping protocol were identical in
both groups. Despite randomization, mean BMI and skin-to-
stone distances were significantly higher in the FS group (p
= 0.001 for BMI and 𝑝 < 0.001 for skin-to-stone distances).
The mean total energy used during an SWL session was
significantly higher in the FS group compared to theUS group
(53 Joule compared to 49 Joule, p = 0.002).
3.2. Comparison of the Clinical Outcome. The stone-free rate
was 52% (34/57) in the US-guided group (95% confidence
interval 39.9%–65%) compared to 42% (24/57) in the FS-
guided group (95% confidence interval 30.1%–55%) (Table 1).
Superioritywas testedwith aChi–Square test for independent
data. The stone-free rate was not significantly different in
both groups (p = 0.06). The success rate was estimated to
be 10% (confidence interval 7.8% to 28.2%) higher for the
US-guided group compared to the FS-guided group. The
confidence interval contained value zero thus noninferiority
of ultrasound was proven.
The positive outcome rate (stone-free or asymptomatic
residual fragments) was 79% (45/57) in the US-guided group
(confidence interval 66.7%–87.5%) compared to 70% (40/57)
in the FS-guided group (confidence interval 57.3%–80.5%)
(Table 1). Superiority was tested with a Chi–Square test
for independent data. The positive outcome rate was not
significantly different in both groups (p = 0.28). The success
rate was estimated to be 9% (confidence interval 7.4% to
24.6%) higher for the US-guided group compared to the FS-
guided group. The confidence interval contained value zero
thus noninferiority of ultrasound was proven.
3.3. Total Number of SWL Sessions. Themean number of SWL
sessions was 1.6 (91 SWL sessions/57 patients) in the US-
guided group compared to 1.7 (97 SWL sessions/57 patients)
in the FS-guided group and was not significantly different (p
= 0.4).
3.4. Positioning Time and Position Adjustments. The mean
time to position patients on the SWL table was significantly
different between the two groups (𝑝 < 0.001) with 9 minutes
in the US group compared to 5 minutes in the FS group
(Table 1).
Despite a fixed protocol to reposition patients the mean
number of position changes was 8 in the US group compared
to 6 in the FS group (p = 0.008) (Table 1).
3.5. Radiation Exposure. We were able to visualize all the
stones of the patients that were randomized with the allo-
cated visualization method. Mean dose area product was
3005mGy/cm2/SWL session in the FS group. Mean fluo-
roscopy time was 178 seconds. No radiation was used during
the SWL procedures in the US group (Table 1).
4. Discussion
Radiopaque stones in the upper urinary tract can often be
visualized both by ultrasonography and fluoroscopy during
SWL treatment. Not all urologists have an ultrasound system
that can be coupled to their SWL machine or they are not
familiar or experienced with this ultrasound-guided SWL
technique.The use of fluoroscopy is easier andmay save some
time. In our study, the mean time to position a patient in the
US group was almost double the time to position a patient
in the FS group. The mean difference however was only 4
minutes which is very limited, especially when the complete
duration of an SWL procedure (up to one hour) is taken
into account. This prospective study was performed with the
intention to compare the results of SWLwhen bothUS and FS
are possible. The study was intentionally limited to proximal
ureter and renal calculi, since calculi in lower positions may
be difficult to visualize with ultrasonography.
A major advantage of ultrasound is that it allows real
time monitoring of the SWL procedure by using hit/miss
monitoring through spectral Doppler ultrasound (SDU) [12].
Although theoretically this SDU technique could lead to
a more accurate aiming of the shock wave because of the
auditive and visual feedback, it is unknown whether this
technical advantage also has a clinical advantage. To our
knowledge, this study is the first to prospectively compare
the clinical results of SWL guided with US (with real time
monitoring) and fluoroscopy (with intermittent fluoroscopy).
The clinical results after SWL in our study showed that
the chance of having a stone-free status or a positive outcome
after US-guided ESWL treatment was slightly higher than
after FS-guided SWL treatment (Table 1). A possible expla-
nation for this difference might be the real time monitoring
which led to a significantly higher number of repositioning
in the US group.The difference, however, was not statistically
significant. Using a noninferiority design, our study was able
to prove that the noninferiority limit of 10% was easily met.
This means that the clinical results of US-guided SWL were
not inferior to FS-guided SWL. The mean number of SWL
sessions needed to reach an endpoint, a secondary outcome,
was not significantly different in both groups. Based on these
results, we can only conclude that US is not inferior to FS.
Another important advantage of ultrasound is that it
does not use ionizing radiation. In our study the mean
fluoroscopy time was 178 seconds and the mean DAP was
3005mGy/cm2/SWL session. Although this is not a wor-
risome dose compared to other interventional procedures,
we need to bear in mind the cumulative effect of ionizing
BioMed Research International 5






Factors influencing SWL outcome
Stone-related factors
Stone size
Mean stone size (mm)(1) 9 (𝜎 = 3) 8.5 (𝜎 = 3) 𝑝 = 0.29
Number of stones 0–4mm 5 5 𝑝 = 1
Number of stones 5–9mm 30 30 𝑝 = 1
Number of stones 10–20mm 22 22 𝑝 = 1
Stone composition(2)
Number of hard stones(3) 6 (𝑛 = 30) 4 (𝑛 = 25) 𝑝 = 0.50
Stone position
Number of lower pole stones 22 (39%) 22 (39%) 𝑝 = 1
Number of pyelum and PUJ stones 5 (9%) 8 (14%) 𝑝 = 0.37
Number of upper pole stones 18 (31%) 8 (14%) 𝑝 = 0.02
Number of midpolar stones 12 (21%) 19 (33%) 𝑝 = 0.14
Stone density (HU)(4)
Mean stone density (HU) 665 (𝜎 = 160, 𝑛 = 31) 740 (𝜎 = 223, 𝑛 = 29) 𝑝 = 0.10
Maximal stone density (HU) 965 1213 NA
Operator-related factors
Experience with both techniques 2 investigators with equal experience NA
Patient-related factors
Mean BMI (kg/m2) 27 (𝜎 = 3,8) 29 (𝜎 = 3,3) 𝑝 = 0.001
Mean skin-to-stone distance (mm)(5) 90 (𝜎 = 13, 𝑛 =31) 104 (𝜎 = 14, 𝑛 = 29) 𝑝 < 0.001
Technique-related factors
Shock frequency (bpm) 60 𝑝 = 1
Number of shocks 2500 𝑝 = 1
Ramping protocol Identical in both groups NA
Mean energy (Joule) 49 (𝜎 = 11) 53 (𝜎 = 11) 𝑝 = 0.002
Study outcomes
Clinical outcome
Number of stone-free patients 30 24 Noninferior(6)
Number of patients with asymptomatic residual fragments 15 16
Number of patients with a positive outcome(7) 45 40 Noninferior(6)
Number of patients needing additional therapy 6 9
Number of patients with no effect 6 8
Number of patients with a negative outcome(8) 12 17 Noninferior(6)
Number of ESWL sessions
Mean number of SWL sessions/patient 1.6 (𝜎 = 0,7) 1.7 (𝜎 = 0,7) 𝑝 = 0.431
Positioning
Mean number of position changes/patient 8 (𝜎 = 2) 6 (𝜎 = 2) 𝑝 = 0.008
Mean time to position/patient 9 (𝜎 = 2) 5 (𝜎 = 2) 𝑝 < 0.001
Radiation
Mean DAP (mGy/cm2)/SWL session 0 3005 (𝜎 = 601) 𝑝 < 0.001
(1)Measured as longest stone distance on RX before the first SWL session. (2) Only 55/114 (48%) patients analysed their stone. (3) Calcium oxalatemonohydrate
(whewellite), cystine, or calcium phosphate (brushite) stones. (4) Hounsfield units as measured on CT abdomen. (5) Measured vertically in the US group and
45∘ in the FS group. (6) With a noninferiority margin of 10%. (7) Stone-free or asymptomatic residual fragments ≤ 4 mm. (8) Additional therapy or no effect.
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radiation. Patients may undergo more than one SWL session
for the same stone. They might experience multiple stone
episodes and multiple diagnostic imaging studies before
and between SWL procedures. Imaging studies may also be
performed for other purposes. Also, the operator’s exposure
to ionizing radiation should be taken into account [18].
Interestingly, however, Ordon and colleagues demonstrated
that a small but significant increase in fluoroscopy time
correlated with an increase in SWL success rates [19].
In our center, about 1/3rd of all stones for which SWL
treatment is indicated can be visualized both by ultrasonog-
raphy and fluoroscopy and in these cases we currently prefer
to avoid radiation by using ultrasonography.
The major limitation of our study is the relatively small
number of patients. A second limitation is the significant
difference in BMI, skin-to-stone distances, and energy used
during an SWL procedure between both groups despite
randomization. It is known that a higher BMI and skin-to-
stone distance may have a negative effect on SWL success
[7, 8]. On the other hand, an insufficient energy level may
have a negative effect on SWL success in the US group if
the threshold energy level to achieve an appropriate stone
disintegration is not reached [4]. It remains unknown to what
extent these differences bias our study results considering
the numerous factors that influence the clinical outcome of
SWL.
The randomized prospective nature of the study and the
fact that all SWL sessionswere carried outwith a standardized
protocol on a single SWLmachine confirm the strength of our
study.
5. Conclusion
Our study demonstrates that US-guided SWL is not inferior
to fluoroscopy-guided SWL, with the additional advantage
of avoiding ionizing radiation. Although more research is
needed to substantiate our findings, we would suggest to
perform ultrasound-guided SWL whenever possible.
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